Bruce E. Tomczuk, PhD
Collegeville, PA * 610.999.7482 * tomczuk@aol.com

PHARMACEUTICAL R&D LEADER * SCIENTIFIC DUE DILIGENCE

PROFESSIONAL PROFILE

Dynamic and intuitive leader known for broad understanding of biotech and pharmaceutical industries. Extensive experience in biology, chemistry, metabolism (ADME), pharmaceutical properties, and translational medicine. Unique and proven ability to combine project management and scientific staff supervisory skills, resulting in successful drug discovery and development. Inventor of 47 pharmaceutical patents. Focusing on a leadership role in research and development at a private /VC funded start-up company.

AREAS OF EXPERTISE

KEY ACCOMPLISHMENTS

• Successfully transitioned five unique research projects into early development.

• Three currently in Phase II & two initiated from lab discoveries.

• Experienced in chemistry start-up activities (12^th employee at 3DP).

• Excellent oral and written communications to Senior-level Management.

“Bruce has a well developed instinct for drug discovery and development. He commands a broad understanding of biology, analytical methods, medicinal chemistry, metabolism, structure-based drug design and general pharmaceutical sciences. If Bruce can’t identify a suitable drug candidate, it is doubtful that anyone else can.”

Christopher Molloy, PhD

Dean, Ernest Mario School of Pharmacy, Rutgers University

Former, Senior Research Fellow and Team Leader, Johnson & Johnson PRD, LLC

PROFESSIONAL EXPERIENCE

Arginetix, Inc. November, 2008-present

Vice-President, Research & Development

Lead the discovery and development efforts on arginase inhibitors as therapeutic agents for endothelial dysfunction.  Initiate and manage outsourcing activities such as medicinal chemistry, protein production, pharmacokinetics, efficacy studies, and toxicology studies. 

Johnson & Johnson PRD, LLC, Exton, PA 2004-2007

Team Leader, Research Fellow, Inflammation and Pulmonary Diseases Team (IPD)

Lead 9 chemists and indirectly manage 20 biologists, responsible for advancement of research projects that are capable of delivering Early Development candidates. Initiate validated rheumatology and pulmonary targets, implement screening assays, optimize screening hits through medicinal chemistry and biochemically and pharmacologically characterize candidate compounds.

• Since 2004, the IPD team transitioned 4 research projects into Early Development.

• Cross-functional collaborations with Global Support Groups within J&J to advance projects.

• Contributed to translational science on Compound Development Teams.

• Solicited, evaluated, and championed in-licensing opportunities.

• Collaborated in transition activities surrounding the acquisition of 3-Dimensional Pharmaceuticals, Inc. while maintaining relationships with key partners.

• Received J&J “Excellence in Science” award in 2005.

3-Dimensional Pharmaceuticals, Inc., Exton, PA (3DP) 1994-2004

Executive Director, Analytical Chemistry, Pharmacokinetics, and Medicinal Chemistry (1999-2004)

Senior Director, Analytical and Medicinal Chemistry (1998-1999)

Distinguished Research Fellow, Analytical and Medicinal Chemistry (1994-1998)

Initiated outsourcing activities such as toxicology studies, GMP scale-up, and GLP manufacture of clinical trial material. Collaborated with external CROs to write the investigators brochure and the IND.

Led discovery of orally active thrombin inhibitor that was a key value driver in the IPO of the company and the acquisition by J&J in 2003.

• Planned the Phase I clinical trial for above agent; trial successfully completed with 54 volunteers and zero errors.

• Initiated state-of-art physicochemical and pharmacokinetic analysis group at 3DP.

• Implemented state-of-art automated purity analysis of combinatorial chemistry libraries.

• Directed 40 personnel in metabolism, analytical and medicinal chemistry groups.

Sterling-Winthrop PRD, Collegeville, PA 1986-1994

Research Leader, Medicinal Chemistry Department (1993-1994)

Senior Research Scientist, Life Sciences Research (1991-1993)

Project Leader, Life Sciences Research (1987-1991)

Program Coordinator, Life Sciences Research (1986-1987)

• Researched metalloenzyme inhibitors based on structure-based drug design principles using x-ray structures and molecular modeling systems.

• Acquired team leadership, people and management, and conflict resolution skills as part of Eastman Kodak training program (acquired Sterling-Winthrop in 1990).

A.H. Robins Company (merged Wyeth), Richmond, VA 1979-1986

Research Associate

Researched central nervous system (CNS) agents producing pre-clinical candidates resembling the marketed drugs Ambien and Lunesta

PROFESSIONAL AFFILIATIONS

Inflammation Research Association, 2003-present

Inflammation Research Association Board Member, 2006- present

Current Topics in Medicinal Chemistry Editorial Advisory Board, 2007

American Chemical Society, 1974-present

American Chemical Society- Medicinal Chemistry Section

American Chemistry Society- Rochester, NY Section

Finance Committee Chairman, 1990-1992

Speakers Committee Co-chairman, 1989

Inflammation Research Association: Organizer and Co-Chair for 2006 symposium

Inflammation Research Association: 15^th International Conference Symposium Co-chair, 2008

EDUCATION

University of Connecticut, Storrs, CT, PhD Medicinal Chemistry

University of Connecticut, Storrs, CT, B.S. Chemistry, Mathematics